JournalsHub
.online
Find My Journal
LA

Lucia Antràs

Analysis Group (United States) US

29
Publications
309
Citations
8
H-Index
6
i10-Index
0
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Publications

0 total

Improved renal function in patients switched from zoledronic acid to ibandronate: A retrospective review of medical records

I. Diel, R. Weide, H. Köppler, L. Antràs, M. Smith - Unknown Venue, 2016
Cited by 0 Semantic Scholar

Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.

D. Cella, A. Pickard, M. Duh, A. Guerin, N. Mishagina - European Journal of Cancer, 2012
Cited by 48 Semantic Scholar

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.

A. Elfiky, D. Cho, D. McDermott, J. Rosenberg, B. Fortner - Urologic oncology, 2011
Cited by 9 Semantic Scholar

PCN50 COSTS OF TREATMENT WITH ANGIOGENESIS INHIBITORS (AIS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RESULTS FROM A MEDICAL CHART REVIEW STUDY OA

W. Oh, D. McDermott, Duh, L. Antràs, Kristina S Chen - Unknown Venue, 2010
Cited by 0 Semantic Scholar

Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review. OA

MeiSheng Duh, R. Weide, H. Köppler, L. Antràs, Michaella J. Smith - Journal of Cancer Research and Therapeutics, 2010
Cited by 42 Semantic Scholar

PCN51 HEALTH CARE COSTS ASSOCIATED WITH ANGIOGENESIS INHIBITORS (AIS) AND MTOR INHIBITORS (MTORS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) TREATED AT US COMMUNITY ONCOLOGY CLINICS OA

Kristina S Chen, S. Sarda, L. Antràs, S. Whittemore, A. Luka - Unknown Venue, 2010
Cited by 1 Semantic Scholar

Patterns of treatment (trx) with angiogenesis inhibitors (AIs) in patients (pts) with metastatic renal cell carcinoma (mRCC) in France.

A. Lévy, M. Gross-Goupil, S. Sarda, C. Korves, L. Antràs - Unknown Venue, 2010
Cited by 0 Semantic Scholar

Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice‐based on medical chart review

T. Choueiri, M. Duh, J. Clement, A. J. Brick, Miranda Rogers - BJU International, 2010
Cited by 63 Semantic Scholar

PUK1 INCIDENCE AND COST OF ADVERSE EVENTS (AES) IN PATIENTS WITH RENAL CELL CARCINOMA (RCC) TREATED WITH ANGIOGENESIS INHIBITORS (AIS) OA

E. Dial, Duh, L. Antràs, D. Rodermund, M. Neary - Unknown Venue, 2010
Cited by 0 Semantic Scholar

Research Topics

Renal cell carcinoma treatment (12) Bone health and treatments (7) Lung Cancer Research Studies (7) Economic and Financial Impacts of Cancer (7) Cancer Genomics and Diagnostics (6)

Affiliations

Roche (United States)
US 2007 - 2007
Harvard University
US 2009 - 2009
GlaxoSmithKline (United Kingdom)
GB 2007 - 2007
GlaxoSmithKline (United States)
US 2009 - 2009
Dana-Farber Cancer Institute
US 2009 - 2009

External Profiles

OpenAlex Profile Semantic Scholar Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now